(PharmaNewsWire.Com, September 11, 2017 ) Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The occurrence and mortality rate of pancreatic cancer market is more in men than in women. Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. And it is expected to become 2nd by 2020.
Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice. The developed tumor hinders the normal functioning of pancreas. The biggest risk factor which leads to pancreatic cancer is smoking. Apart from lifestyle dependent factors like alcohol consumption, obesity and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer. Pancreatic cancer patients lose 98% of their healthy life expectancy at the point of diagnosis itself.
Pancreatic cancer mortality rates are increasing in many countries across the continent, and it is estimated it will cause 91,500 deaths next year. Clearly, this is also the most challenging aspect that this market needs to address. Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Based on the type of treatment, the market has been classified into surgery, chemotherapy, radiation therapy and others. By type, the market has been further segmented as exocrine pancreas cancer and endocrine pancreas cancer. And by end users as hospitals, clinics, research institutes and others. Futhermore, on the basis of geography, the Europe market is analysed under various regions namely UK, Spain, Italy, Germany and France. Globally North America is the largest market for pancreatic cancer. Europe is expected to be the second-largest market for pancreatic cancer. Key players in the pancreatic cancer market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
